CD274 and neoplasm: Tumor-bearing PBL-NOG-hIL-4-Tg mice, which suppress GVHD, demonstrated the effectiveness of atezolizumab, an anti-PD-L1 monoclonal antibody, and a progesterone cancer drug against the triple-negative breast cancer cell line MDA-MB-231 in vivo (Kametani et al., 2023).